The t(14;20) translocation, present in around 2% of Multiple Myeloma cases is one of seven recurrent IGH translocations that are referred to as primary oncogenic events in Multiple Myeloma cases. These translocations result in a transcription product that dysregulates further controlling genes such as the cyclin family of cell cycle control genes which then disrupts normal cell division. As a result of the translocation the transcription of the IGH-MAFB fusion product is up-regulated which has been shown to cause overexpression of Cyclin D3 in around 7% of tumours.
For Research Use Only. Not for use in diagnostic procedures.
Store at minus 20 centigrade
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.